Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism
Zhenqiang Yao, Lianping Xing, Brendan F. Boyce
Zhenqiang Yao, Lianping Xing, Brendan F. Boyce
View: Text | PDF
Research Article

NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism

  • Text
  • PDF
Abstract

TNF and RANKL mediate bone destruction in common bone diseases, including osteoarthritis and RA. They activate NF-κB canonical signaling directly in osteoclast precursors (OCPs) to induce osteoclast formation in vitro. However, unlike RANKL, TNF does not activate the alternative NF-κB pathway efficiently to process the IκB protein NF-κB p100 to NF-κB p52, nor does it appear to induce osteoclast formation in vivo in the absence of RANKL. Here, we show that TNF limits RANKL- and TNF-induced osteoclast formation in vitro and in vivo by increasing NF-κB p100 protein accumulation in OCPs. In contrast, TNF induced robust osteoclast formation in vivo in mice lacking RANKL or RANK when the mice also lacked NF-κB p100, and TNF-Tg mice lacking NF-κB p100 had more severe joint erosion and inflammation than did TNF-Tg littermates. TNF, but not RANKL, increased OCP expression of TNF receptor–associated factor 3 (TRAF3), an adapter protein that regulates NF-κB p100 levels in B cells. TRAF3 siRNA prevented TNF-induced NF-κB p100 accumulation and inhibition of osteoclastogenesis. These findings suggest that upregulation of TRAF3 or NF-κB p100 expression or inhibition of NF-κB p100 degradation in OCPs could limit bone destruction and inflammation-induced bone loss in common bone diseases.

Authors

Zhenqiang Yao, Lianping Xing, Brendan F. Boyce

×

Figure 6

TNF-induced TRAF3 negatively regulates osteoclastogenesis through NIK.

Options: View larger image (or click on image) Download as PowerPoint
TNF-induced TRAF3 negatively regulates osteoclastogenesis through NIK.
(...
(A) WT mouse OCPs were treated with RANKL and/or TNF for 8 hours, and whole-cell lysate protein was extracted and subjected to Western blotting for TRAF3, TRAF6, NIK, and NF-κB p100 and p52. (B) Cycloheximide (10 μM) was added to WT mouse OCPs treated with RANKL (10 ng/ml), TNF (20 ng/ml), or PBS control for the indicated times. Whole-cell lysates were subjected to Western blotting for TRAF3. (C) WT mouse OCPs were transfected with TRAF3 siRNA or a nonspecific control siRNA for 8 hours. The cells were treated with TNF (20 ng/ml) or PBS for an additional 8 hours. Whole-cell lysates were subjected to Western blotting to determine the levels of cytoplasmic TRAF3, NIK, and NF-κB p100 (left panel) and either nuclear p52 or cytoplasmic p100 and RelB (right panels). (D) TRAF3 siRNA–transfected cells were treated with TNF and/or RANKL (10 ng/ml) for 3 days in the presence of M-CSF to generate osteoclasts. *P < 0.05 vs. control).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts